Targeted TEM8 silencing via the extracellular signal-related kinase (ERK)/B cell lymphoma 2 (Bcl-2) signaling pathway significantly inhibited tumor growth and was anti-angiogenic (Gong et al., 2021). Here, ANTXR1 is linked to neoplasm.